

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**
LISTING OF REFERENCES

September 24, 2007

(Use several sheets if necessary)

ATTORNEY DOCKET NO.

2732.1047-010

APPLICATION NO.

10/526,175

FIRST NAMED INVENTOR

Gary R. Ostroff

371(c) DATE

July 29, 2005

EXAMINER

Pagonakis, Anna

CONFIRMATION NO.

6462

GROUP

1609

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/A.P./	A1	3,903,297	09-02-1975	Robert
/A.P./	A2	4,237,266	12-02-1980	Sugiura, <i>et al.</i>
/A.P./	A3	4,492,540	01-08-1985	Yamamoto
/A.P./	A4	4,810,646	03-07-1989	Jamas, <i>et al.</i>
/A.P./	A5	4,992,540	02-12-1991	Jamas, <i>et al.</i>
/A.P./	A6	5,037,972	08-06-1991	Jamas, <i>et al.</i>
/A.P./	A7	5,082,936	01-21-1992	Jamas, <i>et al.</i>
/A.P./	A8	5,223,409	06-29-1993	Ladner, <i>et al.</i>
/A.P./	A9	5,223,491	06-29-1993	Donzis
/A.P./	A10	5,250,436	10-05-1993	Jamas, <i>et al.</i>
/A.P./	A11	5,506,124	04-09-1996	Jamas, <i>et al.</i>
/A.P./	A12	5,576,015	11-19-1996	Donzis
/A.P./	A13	5,702,719	12-30-1997	Donzis
/A.P./	A14	5,766,571	06-16-1998	Ceriani, <i>et al.</i>
/A.P./	A15	4,810,646	03-07-1989	Jamas, <i>et al.</i>
/A.P./	A16	4,761,402	08-02-1988	Williams, <i>et al.</i>
/A.P./	A17	4,739,046	04-19-1988	DiLuzio, <i>et al.</i>
/A.P./	A18	4,138,479	02-06-1979	Truscheit, <i>et al.</i>
/A.P./	A19	4,707,471	11-17-1987	Larm, <i>et al.</i>
/A.P./	A20	5,032,401	07-16-1991	Jamas, <i>et al.</i>

EXAMINER

/Anna Pagonakis/

DATE CONSIDERED

11/26/2007

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES September 24, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1047-010		APPLICATION NO. 10/526,175	
	FIRST NAMED INVENTOR Gary R. Ostroff		371(c) DATE July 29, 2005	
	EXAMINER Pagonakis, Anna	CONFIRMATION NO. 6462	GROUP 1609	

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/A.P./	A21	5,057,503	10-15-1991	Czop, <i>et al.</i>
/A.P./	A22	5,322,841	11-02-1992	Jamas, <i>et al.</i>
/A.P./	A23	5,320,849	06-14-1994	Hagiwara, <i>et al.</i>
/A.P./	A24	5,488,040	01-30-1996	Jamas, <i>et al.</i>
/A.P./	A25	5,532,223	07-02-1996	Jamas, <i>et al.</i>
/A.P./	A26	5,622,939	04-22-1997	Jamas, <i>et al.</i>
/A.P./	A27	3,943,247	03-09-1976	Komatsu, <i>et al.</i>
/A.P./	A28	5,504,079	04-02-1996	Jamas, <i>et al.</i>
/A.P./	A29	5,401,647	03-28-1995	Tanaka, <i>et al.</i>
/A.P./	A30	5,783,569	07-21-1998	Jamas, <i>et al.</i>
/A.P./	A31	5,817,643	10-06-1998	Jamas, <i>et al.</i>
/A.P./	A32	4,975,421	12-04-1990	Williams, <i>et al.</i>
/A.P./	A33	5,474,984	12-12-1995	Tanaka, <i>et al.</i>
/A.P./	A34	4,946,450	08-07-1990	Erwin
/A.P./	A35	5,663,324	09-02-1997	Jamas, <i>et al.</i>
/A.P./	A36	5,633,369	05-27-1997	Jamas, <i>et al.</i>
/A.P./	A37	5,811,542	09-22-1998	Jamas, <i>et al.</i>
/A.P./	A38	5,849,720	12-15-1998	Jamas, <i>et al.</i>
/A.P./	A39	5,607,677	03-04-1997	Jamas, <i>et al.</i>
/A.P./	A40	5,741,495	04-21-1998	Jamas, <i>et al.</i>

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 11/26/2007
-------------------------------	--------------------------------

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES September 24, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1047-010		APPLICATION NO. 10/526,175	
	FIRST NAMED INVENTOR Gary R. Ostroff		371(c) DATE July 29, 2005	
	EXAMINER Pagonakis, Anna	CONFIRMATION NO. 6462	GROUP 1609	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION	
					YES	NO
/A.P./	B1	WO 02/058711 A1	08-01-2002	Sloan-Kettering Institute for Cancer Research		
/A.P./	B2	WO 2004/030613 A2	04-15-2004	University of Louisville Research Foundation, Inc.		
/A.P./	B3	WO 2006/085895 A2	08-17-2006	Biopolymer Engineering, Inc., <i>et al.</i>		

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 11/26/2007
------------------------------	----------------------------

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES September 24, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1047-010		APPLICATION NO. 10/526,175	
	FIRST NAMED INVENTOR Gary R. Ostroff		371(c) DATE July 29, 2005	
	EXAMINER Pagonakis, Anna	CONFIRMATION NO. 6462	GROUP 1609	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/A.P./	C1	Cheung, N-K. V., <i>et al.</i> , "Oral (1→3), (1→4)-β-D-Glucan Synergizes with Antiganglioside GD2 Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma," <i>Clinical Cancer Research</i> , 8: 1217-1223 (May 2002).
/A.P./	C2	Bohn, J.A., <i>et al.</i> , "(1→3)-β-D-Glucans as Biological Response Modifiers: A Review of Structure-Functional Activity Relationships," <i>Carbohydrate Polymers</i> , 28: 3-14 (1995).
/A.P./	C3	Yan, J., <i>et al.</i> , "β-Glucan, A 'Specific' Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)," <i>Journal of Immunology</i> , 163(6): 3045-3052 (1999).
/A.P./	C4	Wang, S-C., <i>et al.</i> , "Targeting HER2: Recent Developments and Future Directions for Breast Cancer Patients," <i>Seminars in Oncology</i> , 28(6): 21-29 (2001).
/A.P./	C5	Ross, G.D., <i>et al.</i> , "Therapeutic Intervention with Complement and β-Glucan in Cancer," <i>Immunopharmacology</i> , 42(1-3): 61-74 (1999).
/A.P./	C6	Database HCAPLUS on STN (Columbus, OH, USA), No. 137:119657, Cheung, N., "Antitumor Antibody-Enhancing Glucan," WO2002058711A1, 01 August 2002, abstract, see entire abstract.
/A.P./	C7	Database DRUGU on STN (Columbus, OH, USA), AN 1998:11655, Coiffier, B., <i>et al.</i> , "A Multicenter, Randomized Phase II Study of Rituximab (Chimeric Anti-CD20 mAb) at Two Dosages in Patients with Relapsed or Refractory Intermediate or High-Grade NHL (IHG-NHL) or in Elderly Patients in First-Line Therapy," <i>Blood</i> (90, No. 10, Suppl. 1 Pt 1), 510A, 1997, abstract, see entire abstract.
/A.P./	C8	Database DRUGU on STN (Columbus, OH, USA), AN 1990-03601, Srivastava, R., <i>et al.</i> , "Bioactive Polysaccharides from Plants," <i>Phytochemistry</i> , Vol. 28, No. 11, pages 2877-2883, 1989, abstract, see entire abstract.
/A.P./	C9	Borchers, A.T., <i>et al.</i> , "MINIREVIEW: Mushrooms, Tumors, and Immunity," <i>Mushrooms and Immunity</i> , 221(4): 281-293 (1999).
/A.P./	C10	Sveinbjörnsson, <i>et al.</i> , "Macrophage Cytotoxicity Against Murine Meth A Sarcoma Involves Nitric Oxide-Mediated Apoptosis," <i>Biochem. Biophys. Res. Commun.</i> , 223(3): 643-649 (1996).
/A.P./	C11	Xia, Y., <i>et al.</i> , "The γ-Glucan-Binding Lectin Site of Mouse CR3 (CD11b/CD18) and Its Function in Generating a Primed State of the Receptor That Mediates Cytotoxic Activation in Response to iC3b-Opsonized Target Cells," <i>J. Immunol.</i> , 162: 2281-2290 (1999).
/A.P./	C12	Thornton, B.P., <i>et al.</i> , "Analysis of the Sugar Specificity and Molecular Location of the γ-Glucan-Binding Lectin Site of Complement Receptor Type 3 (CD11b/CD18)," <i>J. Immunol.</i> , 156: 1235-1246 (1996).
/A.P./	C13	Ross, G.D., <i>et al.</i> , "Membrane Complement Receptor Type Three (CR3) has Lectin-Like Properties Analogous to Bovine Conglutinin and Functions as a Receptor for Zymosan and Rabbit Erythrocytes as well as a Receptor for iC3b," <i>The Journal of Immunology</i> , 134(5): 3307-3315 (1985).
/A.P./	C14	Ross, G.D., <i>et al.</i> , "Specificity of Membrane Complement Receptor Type Three (CR3) for β-Glucans," <i>Complement</i> , 4: 61-74 (1987).
/A.P./	C15	Cain, J.A., <i>et al.</i> , "Role of Complement Receptor Type Three and Serum Opsonins in the Neutrophil Response to Yeast," <i>Complement</i> , 4: 75-86 (1987).
/A.P./	C16	Suzuki, I., <i>et al.</i> , "Inhibition of Experimental Pulmonary Metastasis of Lewis Carcinoma by Orally Administered β-Glucan in Mice," <i>Chem. Pharm. Bull.</i> , 39(6): 1606-1608 (1991).
/A.P./	C17	Roubey, <i>et al.</i> , "Staurosporine Inhibits Neutrophil Phagocytosis but not iC3b Binding Mediated by CR3 (CD11b/CD18)," <i>The Journal of Immunology</i> , 146(10): 3557-3562 (1991).

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 11/26/2007
------------------------------	----------------------------

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES September 24, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1047-010		APPLICATION NO. 10/526,175	
	FIRST NAMED INVENTOR Gary R. Ostroff		371(c) DATE July 29, 2005	
	EXAMINER Pagonakis, Anna	CONFIRMATION NO. 6462	GROUP 1609	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/A.P./	C18	Ross, G.D., <i>et al.</i> , "CR3 (CD11b, CD18): A Phagocyte and NK Cell Membrane Receptor with Multiple Ligand Specificities and Functions," <i>Clin Exp Immunol</i> , 92: 181-184 (1993).
/A.P./	C19	Muto, Satoshi, <i>et al.</i> , "CR3 (CD11b/CD18) Expressed by Cytotoxic T Cells and Natural Killer Cells is Upregulated in a Manner Similar to Neutrophil CR3 Following Stimulation with Various Activating Agents," <i>Journal of Clinical Immunology</i> , 13(3): 175-184 (1993).
/A.P./	C20	Vetvicka, V., <i>et al.</i> , "Soluble γ - Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor Type 3 (CD11b/CD18) Generates a Primed State of the Receptor Capable of Mediating Cytotoxicity of iC3b-Opsonized Target Cells," <i>J. Clin. Invest.</i> , 98(1): 50-61 (1996).
/A.P./	C21	Vetvicka, V., <i>et al.</i> , "Targeting of Natural Killer Cells to Mammary Carcinoma via Naturally Occurring Tumor Cell-Bound iC3b and beta-glucan-primed CR3 (CD11b/CD18)," <i>J. Immunol</i> , 159(2): 599-605 (1997).
/A.P./	C22	Reddy, R.K., <i>et al.</i> , "A Mixed Population of Immature and Mature Leucocytes in Umbilical Cord Blood Results in a Reduced Expression and Function of CR3 (CD11b/CD18)," <i>Clin Exp Immunol</i> , 114: 462-467 (1998).
/A.P./	C23	Xia, Y., <i>et al.</i> , "Generation of Recombinant Fragments of CD11b Expressing the Functional γ -Glucan-Binding Lectin Site of CR3 (CD11b/CD18)," <i>The Journal of Immunology</i> , 162(12): 7285-7293 (1999).
/A.P./	C24	Vetvicka, V., <i>et al.</i> , "Regulation of CR3 (CD11b/CD18)-dependent Natural Killer (NK) Cell Cytotoxicity by Tumour Target Cell MHC Class I Molecules," <i>Clin Exp Immunol</i> , 115: 229-235 (1999).
/A.P./	C25	Yan, J., <i>et al.</i> , "Critical Role of Kupffer Cell CR3 (CD11b/CD18) in the Clearance of IgM-Opsonized Erythrocytes or Soluble γ - Glucan," <i>Immunopharmacology</i> , 46: 39-54 (2000).
/A.P./	C26	Ross, G.D., "Regulation of the Adhesion Versus Cytotoxic Functions of the Mac-1/CR3/ γ_M2 - Integrin Glycoprotein," <i>Critical Reviews in Immunology</i> , 20:197-222 (2000).
/A.P./	C27	Ross, G.D., "Role of the Lectin Domain of Mac-1/CR3 (CD11b/CD18) in Regulating Intercellular Adhesion," <i>Immunologic Research</i> , 25(3): 219-227 (2002).
/A.P./	C28	Biopolymer Engineering Presentation: Pioneering Carbohydrate Technology to Improve Human Health, April 2003.
/A.P./	C29	Blakeslee, Dennis, "The Two Faces of Immunity: Th1 and Th2," JAMA HIV/AIDS Resource Center, The Journal of the American Medical Association, http://www.ama-assn.org/special/hiv/newsline/briefing/th1.htm (8/12/2002).
/A.P./	C30	"What's the Difference of Th1 Cells and Th2 Cells Effect?" http://www.madsci.org/posts/archives/may99/926272023.Im.r.html (May 8, 1999).
/A.P./	C31	Heron Herbs: Feature Articles: "Balancing Cellular and Humoral Immunity," http://www.healthcalls.net/hh_art1alt.html (8/16/2002).

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 11/26/2007
------------------------------	-------------------------------